Nearly all brain tumors develop following the progressive accumulation of genetic alterations of oncogenes and tumor suppressor genes (such as p53 and retinoblastoma protein). Furthermore, aberrations in the nuclear matrix often contribute to genomic instabilities and the development of cancer. We have previously shown that nuclear-restricted protein/brain (NRP/B), a member of the BTB/Kelch repeat family, is a nuclear matrix protein normally expressed in neurons but not in astrocytes, and that it is an early and specific marker of neurons during the development of the central nervous system. Here, we show aberrant expression of NRP/B in human brain tissues. NRP/B is expressed in the cytoplasm of human brain tumor cells (glioblastoma, GBM) arising from astrocytes. NRP/B mutations (13 mutations in the Kelch domains, two in the intervening sequence (IVS) domain and two in the BTB domain) were detected in brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH and U87-MG) and in primary human malignant GBM tissues (eight samples). More importantly, we found that NRP/B mutants, but not wild-type (wt) NRP/B, increased the activation of ERK and consequently promoted cell proliferation, attenuated caspase activation and suppressed the cellular apoptosis induced by the stressful stimulus cisplatin (10 lM). These events were observed to occur via a p53-mediated pathway. In addition, while wt NRP/B was associated with actin, mutations in the Kelch domains of NRP/B led to its reduced binding affinity to actin. Thus, alterations and gene mutations within the NRP/B gene may contribute to brain tumorigenesis by promoting cell proliferation, suppressing apoptosis and by affecting nuclear cytoskeleton dynamics.
Introduction
Tumors of the central nervous system (CNS) are the second most frequently occurring malignancy of childhood, and their incidence in adults increases with advancing age (Maher et al., 2001; Wechsler-Reya and Scott, 2001; Louis et al., 2002) . There are dozens of different types of CNS tumors recognized by the World Health Organization. Malignant glioblastomas (GBMs), arising from astrocytes or astrocyte progenitors, are the most common and most studied tumors. GBMs are aggressive, highly invasive, and neurologically destructive. Although the etiology of GBMs is unclear, it always involves mutation or overexpression of multiple genes, the products of which are components of signal transduction pathways that control cell cycle entry or exit, promote differentiation, sensitize DNA damage and initiate repair mechanisms, and/or regulate cell death programs. As relevant genes in this process have been identified, such as growth factor receptors (e.g. EGFR) (Libermann et al., 1985a, b) , components of the cell cycle machinery (retinoblastoma protein (pRb), cdk4, and the cdk inhibitor p16) (Schmidt et al., 1994; Ichimura et al., 1996; Biernat et al., 1998; Collins, 1998; Rasheed et al., 1999; Simon et al., 1999) , and regulators of apoptosis (p53, mdm2, AFR, and PTEN) (Biernat et al., 1998; Besson et al., 1999; Cantley and Neel, 1999; Rasheed et al., 1999; Simon et al., 1999; Di Cristofano and Pandolfi, 2000; Ichimura et al., 2000) , novel and potent therapies for CNS tumors might be based on blockade of signal transduction, restoration of cell cycle control, and inhibition of 'effector' molecules. Virally mediated gene transfers of functional p16, pRb, or p53, and mTOR inhibition with rampamycin analogs to restore the G1/S checkpoint are examples of glioma therapies under development (Grim et al., 1997; Campbell et al., 2000; Lane and Lain, 2002) .
The nuclear matrix, defined as the insoluble framework of the nucleus, has been implicated in modulating gene expression, the cell cycle, and nuclear structure integrity via linkage to intermediate filaments of the cytoskeleton (Bode et al., 2000; Sotolongo and Ward, 2000; Davie and Spencer, 2001) . Nuclear structural alterations are prevalent in cancer cells and commonly used as pathological markers of transformation in many types of cancer (Dardick et al., 1981; Getzenberg et al., 1996; Konety and Getzenberg, 1999; Davido and Getzenberg, 2000; Saunders et al., 2000; Brunagel et al., 2002) . Furthermore, changes in the framework or composition of the nuclear structural framework may result in the transformation of normal cells to a malignant state by affecting transcription, replication, and/or other nuclear processes (Konety and Getzenberg, 1999; Alberti et al., 2000; Meyers and Hiebert, 2000; Stein et al., 2000; Brunagel et al., 2002) . The discovery of a matrix constituent whose normal expression is neural specific may also offer a new area for brain research.
We have discovered and characterized a novel neuronal nuclear matrix protein, nuclear-restricted protein/brain (NRP/B), which contains a BTB/POZ domain-like structure in the N-terminus and six copies of Kelch repeats in the C-terminal region (Kim et al., 1998) . This protein, also termed ectodermal-neural cortex (ENC-1) (Hernandez et al., 1997) , has been implicated in a variety of processes such as transcription, the regulation of gene expression, cell cycle, and organization of the cytoskeleton (Hernandez et al., 1997; Kim et al., 1998 Kim et al., , 2000 Zhao et al., 2000) . NRP/B is expressed during early gastrulation in the prospective neuroectodermal region of the epiblast and, later, in the nervous system where it is mainly localized in the nucleus of neurons (Kim et al., 1998) . Our previous studies showed that NRP/B interacts with p110 RB and may be involved in neuronal differentiation (Kim et al., 1998) . Moreover, the expression of NRP/B is frequently elevated and appears in non-neuronal cells in brain tumors including GBMs and astrocytomas , suggesting its possible involvement in brain tumor development.
To study the role of NRP/B in brain tumorigenesis, we compared NRP/B expression patterns in brain tumors and normal brain, and analysed NRP/B gene sequences in four brain tumor cell lines and eight primary human brain tumor (GBM) samples. In addition, we investigated the effects of NRP/B on cell growth and apoptosis, and studied the molecular mechanisms by which NRP/B may mediate its effects on brain tumor development. Understanding the role of NRP/B in brain tumor development may assist in the discovery of novel and potent therapies for brain tumors.
Results

Expression of NRP/B in normal human brain and human malignant brain tumors
Strong NRP/B expression was observed in neurons from the cortex of normal human adults by immunostaining with a specific NRP/B antibody. Positive staining was mainly localized in the nucleus of the neurons (Figure 1a , panels a and b). While NRP/B expression was not detected in the non-neuronal cells of the normal brain, its expression was observed in brain tumor (GBM) cells arising from astrocytes or astrocyte progenitors. In addition, while NRP/B expression was found in the nucleus in primary neurons, its expression was mainly observed in the cytoplasm in brain tumors (Figure 1a , panels c and d). Reverse transcription-PCR (RT-PCR) analysis using specific primers for NRP/B further confirmed that NRP/B was expressed in primary neurons, brain tumor cell lines and GBM cells, but not in primary normal astrocytes (Figure 1b ). These data suggest that changes in NRP/B localization and expression may be associated with the development of brain tumors.
Mutations of NRP/B in brain tumor cell lines and primary brain tumors (GBMs)
To further investigate the involvement of NRP/B in brain tumorigenesis, we analysed NRP/B gene sequences from four brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH, and U87-MG) and eight primary GBM tissues. Mutations (A535V and I549T) in the Kelch domain of NRP/B were detected in CCF-STTG1 and U87-MG cell lines, respectively; mutations (A293T) in the intervening sequence (IVS) domain were seen in SK-N-SH cells; and mutations (V266A; F333L) in both the Kelch and IVS domains were found in A-172 cells (Table 1) . We also observed mutations of NRP/B in all eight primary GBM tissues (Table 2) : nine mutations (H381T, H381I, L403F, N436T, Q463R, two C531R, Notes: A-172 -glioblastoma; CCF-STTG1 -astrocytoma; SK-N-SH -neuroblastomas; U87 -GBM-astrocytoma Table 2 and as described in Table 3 . As seen in Figure 2a , oligodendroglial type 2 astrocyte (O2A) cells transfected with mutated NRP/B showed a high proliferation rate as compared to cells overexpressing wt NRP/B. It is well known that the activation of ERK/MAPK and AKT plays a critical role in cell proliferation and malignant progression. To dissect the molecular mechanism by which mutated NRP/B elevates cell proliferation and contributes to malignancy, we tested whether activation of these molecules is involved in the cell proliferation induced by mt NRP/B. We found that mutated NRP/B (24 h after transfection) increased ERK activation (Figure 2b 
Effects of mutated NRP/B isolated from primary brain tumors on the apoptosis machinery
The NRP/B isoform known as p53-induced protein 10 (PIG 10) was shown to be identical to NRP/B, but contains multiple mutations and deletions (Polyak et al., 1997) . We first analysed whether p53 activated the NRP/ B promoter. In agreement with the previous study (Polyak et al., 1997) , we observed that p53 activated the promoter of NRP/B (Figure 3a ) and regulated NRP/B expression (Figure 3b and c). Apoptotic induction is a key component of p53's tumor suppression (Symonds et al., 1994; Gottlieb and Oren, 1998) . p53 has been suggested to mediate its apoptotic functions through two pathways: death receptors and activation of caspases (Levine, 1997; Vousden, 2000; Nakano and Vousden, 2001) . Caspase-3 is a key executor of the cell death pathways (Ye et al., 1999; Schuler et al., 2000; Kumar and Vaux, 2002) . It has been suggested that PIG 10 may be involved in the p53-dependent cell death pathway (Polyak et al., 1997) . To classify whether NRP/ B mutations lead to brain tumorigenesis by affecting the p53-mediated apoptosis machinery, we compared the effects of wt and mutated NRP/B on apoptosis in HCT 116 cells (kindly provided by Dr Vogelstein). These HCT 116 cells are human colon cancer cells, and the HCT 116 cell line has shown the lowest expression of NRP/B among 11 colon cancer cell lines examined (Polyak et al., 1997) . Figure 4a shows that HCT 116 p53 þ / þ cells transfected with mutated NRP/B constructs were resistant to apoptosis in response to cisplatin treatment (10 mM, 12 h), whereas wt NRP/Boverexpressing and untransfected cells were sensitive to the stress. Of note, untreated cells or mock-transfected cells were also sensitive to the stress induced by cisplatin, although to a lesser extent as compared to mutated NRP/B. Furthermore, we found that transfection of mutated NRP/B constructs into HCT 116 p53 þ / þ cells attenuated the caspase-3 activation induced by cisplatin treatment (Figure 4b ) that was observed before apoptosis occurred. Overexpression of a wt NRP/B construct in HCT 116 p53À/À cells restored caspase-3 activation and increased apoptotic responses induced by cisplatin treatment (Figure 4c and d) . Thus, p53 binding to the NRP/B promoter may result in the upregulation of transcription, while p53 binding to mutated NRP/B may disrupt this regulation, and consequently affect the apoptosis machinery.
Role of the Kelch motif of NRP/B in the organization of the nuclear structure It has been suggested that NRP/B plays a role in the organization of the cytoskeleton and nuclear structures through the association of its Kelch domain with actin (Hernandez et al., 1997; Kim et al., 1998 Kim et al., , 2000 . Here, we demonstrated that the full-length NRP/B or the Cterminus of NRP/B (Kelch-NRP/B, 296-589 amino acids) binds directly to actin, by using far Western blot analysis (Figure 5a ). Csk kinase was used as a negative control for actin binding properties. NIH 3T3 cells in which NRP/B was not detected were transfected with either wt or mutated NRP/B. At 48 h after transfection, cells were lysed and processed for the immunoprecipitation assays. These assays showed that mutated NRP/B1 (E96K, C531R) and mutated NRP/B2 (N216S, Q463R) had significantly lower binding affinity to actin as compared to the wt NRP/B, and that mutated NRP/ B3 (with deletion of four Kelch domains) had no binding affinity to actin (Figure 5b, upper panel) . 
Discussion
Genes and signal cascades that play important roles in the development of the nervous system by controlling proliferation, differentiation, the maintenance of homeostasis, and cytoskeletal organization have been Role of NRP/B in brain tumors X-Q Liang et al implicated in brain tumor development. Recently, we have characterized a neuron-specific nuclear matrix protein, NRP/B, which is a member of the BTB/Kelch repeat family. NRP/B is an early marker of the nervous system and may play a role in the development of the CNS by interacting with p110 RB and by functioning as an actin-binding protein (Hernandez et al., 1997; Kim et al., 1998) . NRP/B expression is frequently elevated in human brain tumors and appears in brain tumor cells originating from non-neuronal cells, including GBMs and astrocytomas . In the present study, we observed that NRP/B was expressed in the neural region of the normal adult brain and was mainly localized in the nucleus of neurons (Figure 1a , panels a and b). However, NRP/B was also expressed in brain tumor cells (GBM) that arise from astrocytes and was mainly localized in the cytoplasm (Figure 1a , panels c and d). Mutations of NRP/B (13 mutations in the Kelch domains, two in the IVS domain, and two in the BTB domain) occurred in brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH, and U87-MG) (Table 1 ) and in primary GBM tissues (eight samples) ( Table 2 ). More importantly, NRP/B mutations provided a cell growth advantage by elevating ERK activation and suppressing cellular apoptosis in response to stressful stimulus (10 mM cisplatin) by inhibition of p53-mediated caspase activation (Figures 2-4) . We also observed that NRP/B was associated with actin, and that mutations in the Kelch domain of NRP/B reduced its binding affinity to actin ( Figure 5 ). These data suggest that NRP/B may be involved in brain tumorigenesis.
Of note, expression of NRP/B /ENC-1 is most abundant in fetal brain. However, NRP/B is also expressed in fetal kidney, lung, heart, and liver, and this activity is reduced or diminished very significantly in adult organs. Thus, NRP/B may play a crucial role during differentiation in a variety of cell lineages. Consistent with this notion, expression of NRP/B increases dramatically not only in neuroblastoma cells responding to retinoic acid, a differentiation-inducing agent, but also in preadipocytes treated with the phosphodiesterase inhibitor methylisobutyl xanthine (Kim et al., 1998; Zhao et al., 2000) .
The expression of NRP/B is upregulated in various types of brain tumors . Interestingly, enhanced expression of PIG 10 was observed in the majority of colon cancers. Therefore, activation of NRP/B/ENC-1 may be a component in the tumorigenic mechanisms common to colon and brain (Fujita et al., 2001) .
Human tumors develop following the progressive accumulation of genetic alterations to oncogenes and tumor suppressor genes. Genetic alterations occurring in brain tumors affect three major biologic pathways that Louis et al., 2002) . It is well known that inappropriate cell proliferation and/or altered patterns of cell death are tightly linked to the development of brain tumors. Hence, NRP/B may play an important role in brain tumor suppression, and mutations in NRP/B could contribute to brain tumorigenesis by affecting cell proliferation, apoptosis, and nuclear structure.
The extracellular signal-regulated kinases include ERKs, JNKs, and p38 mitogen-activated protein kinase. The ERK pathway has a major role in cell proliferation and tumorigenesis. Expression of constitutively active forms of components of this pathway can transform cells (Kyriakis et al., 1992 (Kyriakis et al., , 1994 Mansour et al., 1994) . There is a growing body of evidence suggesting that the elevated activation of ERK is associated with several human cancers (Sivaraman et al., 1997; Mandell et al., 1998; Xing and Imagawa, 1999; Antonyak et al., 2002) . In the present study, we found that NRP/B mutations elevated ERK activation that was followed by high cell proliferation, and that inhibition of ERK activation using its specific inhibitor PD98059 attenuated cell proliferation (Figure 2) . Moreover, NRP/B mutations had no effect on the activity of JNK, p38, and AKT. Hence, NRP/B mutations may contribute to brain tumorigenesis by promoting cell proliferation through the ERK pathway.
It is well known that the p53 pathway plays a pivotal role in the suppression of brain tumors. p53 prevents tumorigenesis by inhibiting cell growth and inducing apoptosis in both human and mouse. It responds to a variety of cellular stresses, such as DNA damage, hypoxia and aberrantly activated oncogenes, and initiates a transcriptional program that can trigger either cell-cycle arrest or apoptosis (Levine, 1997; Prives and Hall, 1999) . In this manner, p53 monitors genome integrity, and when necessary, activates mechanisms that allow DNA damage to be repaired or damaged cells to be eliminated via apoptosis. Owing to its essential role in genome surveillance, mutations of the p53 gene or inactivation of its activity are the most frequently occurring events associated with human cancers (Levine, 1997; Vogelstein et al., 2000; Vousden, 2000) . The loss of p53 function is the earliest and most common genetic lesion observed in GBMs (Sidransky et al., 1992) . About 30-40% of human GBMs carry mutations in p53 (Bogler et al., 1995; Reilly and Jacks, 2001 ). Apoptotic induction is a key component of p53's tumor suppression (Symonds et al., 1994; Gottlieb and Oren, 1998) . p53 has been suggested to mediate its apoptotic functions through two pathways: death receptors and activation of caspases (Levine, 1997; Nakano and Vousden, 2001; Vousden and Lu, 2002) . Caspase-3 is the key executor of the apoptotic pathways (Ye et al., 1999; Schuler et al., 2000; Kumar and Vaux, 2002) . p53 functions as a transcriptional factor to regulate a set of genes mediating its functions. Our present study and a previous one demonstrated that p53 regulates NRP/B (Figure 3) (Polyak et al., 1997) and (PIG 10) expression by transcriptional regulation (Figure 3) (Polyak et al., 1997) , and that NRP/B or PIG 10 may be involved in the p53-dependent cell death pathway (Figure 4) (Polyak et al., 1997) . In this study, we also found that transfection of mutated NRP/B expression constructs into HCT 116 p53 þ / þ cells attenuated caspase-3 activation, which was followed by resistance of apoptotic responses to the DNA-damaging reagent -cisplatin (Figure 4a ). Furthermore, we observed that overexpression of wt NRP/B in HCT 116 p53À/À cells restored caspase-3 activation and cell sensitivity to apoptosis in response to cisplatin treatment (Figure 4b ). These results indicate that NRP/B mutations may contribute to brain tumorigenesis by affecting the cellular apoptosis machinery through a p53-mediated caspase pathway.
The pRb also plays a pivotal role in tumor suppression. pRb exerts its tumor suppressor function by controlling cell proliferation and regulating the cell cycle (Lee et al., 1994; Weinberg, 1995; Yang et al., 2002) . Hypophosphorylated pRb prevents premature S phase entry by binding to E2F family members and by recruiting histone deacetylases to the E2F-bound promoters (Brehm and Kouzarides, 1999) . When cells need to re-enter the cell cycle, pRb is phosphorylated by cyclin D-cdk4 and cyclinE-cdk2 complexes, leading to the release of E2Fs and the transcription of genes necessary for S-entry and progression (Nevins et al., 1997) . Defects in pRb or the pRb pathway are critical steps in the development of GBMs (Henson et al., 1994; Ueki et al., 1996; Biernat et al., 1998; Fueyo et al., 1998; Rasheed et al., 1999; Simon et al., 1999; Ichimura et al., 2000) . Mutations in pRb and the pRb-mediated pathway occur in 70-80% of GBMs (Henson et al., 1994; Ueki et al., 1996) . Our previous study showed that NRP/B was highly phosphorylated during cell cycle progression, and that overexpression of NRP/B in PC-12 cells induced neurite outgrowth and growth arrest in the G1/G0 phase of the cell cycle (Kim et al., 1998; Kim et al., 2000) . We recently found that NRP/B inhibits the progression of the cell cycle by interacting with pRb and the components of the pRb pathway via the BTB domain of NRP/B (Kim and Avraham, unpublished data). Relocation of NRP/B from the nucleus into the cytoplasm and/or gene mutations in NRP/B may affect the interaction of NRP/B with pRb and the components of the pRb pathway, resulting in deregulated cell proliferation. Hence, mutations in NRP/B may lead to the development of brain tumors by disrupting the functions of pRb or the pRb pathway. The transformation of normal cells to a malignant state has been detected as visible changes in nuclear structures mediated by nuclear matrices (Konety and Getzenberg, 1999; Alberti et al., 2000) . It is well known that aberrations in the nuclear matrix contribute to the development of cancer (Bode et al., 2000; Davido and Getzenberg, 2000; Sotolongo and Ward, 2000; Davie and Spencer, 2001; Brunagel et al., 2002) . The nuclear matrix, defined as the framework of the nucleus, is known to be important for normal cellular functions such as transcriptional regulation, DNA replication, and protein-protein interactions (Bode et al., 2000; Davido and Getzenberg, 2000; Sotolongo and Ward, 2000; Stein et al., 2000; Davie and Spencer, 2001 ). Furthermore, the nuclear matrix has been shown to be the binding site of various tumor-associated proteins, and therefore may play a role in the specific nuclear protein alterations that initiate and propagate cellular transformation (Deppert et al., 2000; Sotolongo and Ward, 2000; Brunagel et al., 2002) . NRP/B, defined as a novel neuronal nuclear matrix protein, contains a BTB/ POZ domain-like structure in the N-terminus and six copies of Kelch repeats in the C-terminal region (Kim et al., 1998 . It has been implicated in a variety of processes such as transcription, regulation of gene expression, the cell cycle, and organization of the cytoskeleton (Hernandez et al., 1997; Kim et al., 1998 Kim et al., , 2000 Zhao et al., 2000) . NRP/B has been found to associate with nuclear actin via its Kelch domains and to play an important role in the organization of the nuclear structure. Mutations in the Kelch domains of NRP/B reduced or erased NRP/B-actin binding affinity ( Figure 5 ). Thus, mutations in the Kelch domains of NRP/B (Tables 1 and 2) , which occurred in all of the tested brain tumor cell lines and eight primary GBM tissues, might result in alterations to nuclear structures, thereby affecting transcription, DNA replication, and/ or other nuclear processes, leading to oncogenesis.
In summary, NRP/B may play an important role in the suppression of brain tumors. Alteration of NRP/B expression and mutation of the NRP/B gene may contribute to brain tumorigenesis by elevating cell proliferation, suppressing apoptosis, and inducing changes in nuclear structure. Therefore, potent and specific approaches for treating brain tumors may be discovered by targeting NRP/B or its related pathways.
Materials and methods
Preparation of anti-NRP/B antibodies
NRP/B was expressed and purified from Sf-9 cells and polyclonal antibodies against the NRP/B protein were raised in rabbits, according to a standard protocol and as described previously (Kim et al., 1998) . The titers of the antisera were analysed by ELISA and Western blot analysis. Hybridomaproducing monoclonal anti-NRP/B antibodies were raised by the conventional PEG-fusion technique and characterized as described (Kim et al., 1998) Cell culture Human brain tumor cell lines (A-172: GBM; CCF-STTG1: astrocytoma; SK-N-SH: neuroblastoma; and U87-MG: GBM-astrocytoma, PC-12, and NIH3T3 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HCT 116 p53 wt (p53 þ / þ ) and p53 deficient (p53À/À) cells were kindly provided by B Vogelstein. Cells were cultivated in the conditional media as follows: DMEM for A-172 and HCT 116; RPMI 1640 for CCF-STTG1; F12/DMEM mixture for SK-N-SH; and MEM for U87-MG. Each was supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. PC-12 cells were cultivated in DMEM with 5% horse serum and 100 ng/ml NGF. NIH3T3 cells were incubated in MEM with 10% calf serum. The isolated O2A progenitors were seeded in DMEM/HEPES-buffered Earle's balanced salt solution (1 : 1) in Petri dishes coated with 50 mg/ml poly-D-ornithine (Sigma) according to the method described previously (Back et al., 1998) .
Primary neurons were prepared from the hippocampal region of Sprague-Dawley rats at embryonic day 18 and cortical astrocytes were obtained from the rat at postnatal day 1, according to the method described previously (Brewer et al., 1993; Kim et al., 1998 Kim et al., , 2000 .
Histological analysis
The eight GBM and two normal brain (normal frontal cortex) specimens were obtained from CHTN and Beth Israel Deaconess Medical Center. The diagnosis of GBM was performed by neuropathologists. The paraffin-embedded samples were sectioned at 5 mm. Sections were placed on precoated slides (Fisher), dried overnight at 371C and stored at 41C. For immunostaining, sections were incubated with a monoclonal NRP/B antibody (0.1 mg/ml) and detected with an ABC Elite kit (Vector) and 3,3 0 -diaminobenzidine (Vector). For conventional histology, the neighboring sections were stained with hematoxylin and eosin (Vector).
RT-PCR, cloning, and sequencing
Total RNA was isolated from the brain tumor cells, primary neurons and astrocytes, and primary GBM samples by using TRIZOL reagent (Life Technology, Invitrogen) according to the manufacturer's directions. Total RNA (1-5 mg) was used as a template for random-primed cDNA synthesis using a first-strand cDNA synthesis kit (Life Technology, Inc.). The entire NRP/B coding region was amplified by PCR using a forward primer 5 0 -ATGTCAGTCAGTGTGCATGA-GAACCGC-3 0 and a reverse primer 5 0 -AGAAGGCA-GATGTTTCCAGGTGCTGAC-3 0 . Amplified 1768 bp from brain tumor cell lines and primary GBM corresponding to nucleotides 400-2166 of NRP/B cDNA (Gene bank access number: AF059611) using the Expand High Fidelity PCR system (Roche) were ligated into a TA cloning vector (Life Technology, Invitrogen). From each brain tumor cell line and primary GBM sample, several clones were selected and sequenced. To exclude errors, the entire NRP/B coding region from normal human brain tissues was synthesized and sequenced using the same process. To further confirm the mutations, NRP/B cDNA using Pfu DNA polymerase (Stratagene) was also directly used as a template for sequencing. The nucleic acid and protein data banks were searched and aligned with the human NRP/B sequences using the BLAST program.
Constructs and transfection
NheI and BamHI sites were generated close to start code and termination sites, respectively, in wt NRP/B from normal human brain and in mutated NRP/B (mtNRP/B1: N216S, Q463R; mtNRP/B2: E96K, C531R; mtNRP/B3: deletion of four Kelch domains) (see Table 3 ) from human GBM samples by PCR and then subcloned into the expression vector pIRES2-EGFP (Clontech). The transfections were carried out using FUGENE 6 (Roche Molecular Biochemicals) and LIPOFECTAMINEt 2000 reagent (Life Technology, Invitrogen) according to the manufacturer's instructions. The efficiency of transfection was confirmed by a Western blot assay.
Cell proliferation assays
O2A, 293T, and SK-N-SH cells were transfected with either wt or mutated NRP/B expression constructs. At 24 h after transfection, the cells were labeled with 5-bromodeoxyuridine (BrdU, Sigma) for 24 h, then fixed and stained with antibody against BrdU (Becton Dickinson). To determine the effects of inhibiting ERK1/2 activation on cell proliferation in culture, cells were seeded on day 1 and on the following day PD98059 (Calbiochem) was added to a final concentration of 10 mM; after 20 h, BrdU was added for a further 24 h before fixation and staining with antibody against BrdU.
Apoptosis assay
After transfection with either wt or mutated NRP/B constructs for 24 h, HCT 116 cells were cultivated for the apoptosis assay. As a control, cells were transfected with the empty vector. The transfected cells were seeded at 10 3 cells in a six-well plate, exposed to 10 mM of the anticancer drug cisplatin (a DNAdamaging agent) (Sigma) for 12 h, and fixed with 4% PFA for 30 min. The cells were next stained with terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick-end labeling (TUNEL kit, Boehringer Mannheim, Germany), and mounted in Vectashield containing 4 0 , 6-diamidino-2-phenylindole (Vector) nuclear counterstain. Positive cells with DNA fragmentation were counted in triplicate under a fluorescent microscope.
Promoter assay
The transcriptional initiation site of NRP/B was determined using 5 0 -RACE and comparing the human genomic sequence (GenBank Accession No. NT-006596) and the cDNA sequence of NRP/B (GenBank Accession No. AF059611). Total RNA was extracted from the human frontal cortex (Stratagene) and the first-strand cDNA synthesis and 5 0 -RACE were carried out according to the instruction manual of the 5 0 -RACE system (GibcoBRL). Several bands were obtained and cloned into a PCR 4-TOPO vector (Invitrogen). The sequence and human genome analyses revealed the transcriptional initiation site of NRP/B. To examine the promoter activity of NRP/B, the fragment (300-1500 bp) containing p53-responding elements was amplified from genomic DNA (each base pair corresponding to a part of the 5 0 -flanking region of NRP/B by PCR) and was cloned into NheI and BglII enzyme sites of the pGL3-Enhance vector (Promega, Madison, WI, USA). A measure of 0.3 mg each of the reporter plasmids and 0.3 mg wt or mutated p53 expression constructs (pCMV-p53 and pCMV-p53mt, BD Clontech) were cotransfected into U87-MG cells cultivated in a 12-well plate using FUGENE 6 (Boehringer Mannheim, Germany). The reporter assay was carried out using the luciferase reporter assay system according to the supplier's recommendations (Promega).
Semiquantitative RT-PCR
To evaluate the level of NRP/B gene expression, U87-MG cells were transfected with either a pCMV-p53 or pCMV-p53mt expression construct followed by total RNA extraction and single-strand cDNA synthesis. Appropriate dilutions of each single-strand cDNA were prepared for subsequent PCR by monitoring the b-actin gene as a quantitative control. The primers for the NRP/B coding region were the same as described above.
Western blotting
Cells were transfected with NRP/B constructs (either wt NRP/ B or mutated NRP/B) or with p53 constructs (p53 and p53mt). To test ERK activation, 24 h after transfection with NRP/B constructs, total O2A cell lysates were analysed by SDS-PAGE and transferred onto membranes. To test caspase-3 activation, HCT 116 cells transfected with NRP/B constructs were prepared for Western blotting after exposure to cisplatin (10 mM, 6 h). To investigate the regulation of NRP/B by p53, U87-MG cells transfected with p53 constructs were processed for Western blotting. The blots were incubated with specific antibodies (either phospho-ERK, ERK, caspase-3 (BD PharMingen) or NRP/B) followed by reaction with horseradish peroxidase-conjugated IgG. Immunoreactive bands were visualized using ECL reagents.
Far Western blot analysis
For binding experiments, total PC-12 cell lysates were immunoprecipitated with a control antibody or NRP/B monoclonal antibody. The immunoprecipitates were analysed on 7.5% SDS-PAGE and transferred onto membranes. The blots were incubated at 41C overnight in 5% milk in phosphate-buffered saline containing 0.1% Tween-20, followed by incubation with 20 mg of purified tyrosine kinase Csk as a control, full-length NRP/B protein, the C-terminus of NRP/B (296-589 amino acids), or the N-terminus of NRP/B (1-150 amino acids) for 2 h at 41C. The blots were washed and anti-F-actin monoclonal antibody was added for 1 h. After washing, horseradish peroxidase-conjugated anti-mouse IgG was added for 1 h. Immunoreactive bands were visualized using ECL reagents.
Immunoprecipitation
Immunoprecipitation was carried out as described (Kim et al., 1998) . NIH 3T3 cells in which NRP/B was not detected were transfected with either wt or mutated NRP/B constructs. At 48 h after transfection, cells were lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM PMSF, 2 mg/ml aprotinin, leupeptin, and pepstatin, and 1 mM Na 3 VO 4 ). Total cell lysates were clarified by centrifugation at 10 000 g for 10 min. Identical amounts of protein from each sample were precleared by incubation with protein G-Sepharose CL-4B (Sigma) for 10 min at 41C. After the removal of protein G-Sepharose by brief centrifugation, protein concentrations were determined using a protein assay (Bio-Rad Laboratories, Hercules, CA, USA) and cell lysates were incubated with the NRP/B antibody overnight at 41C. Immunoprecipitation of the antigen-antibody complex was accomplished by incubation with 30 ml of protein G-Sepharose for 1 h at 41C. Bound proteins were solubilized in 20 ml of 2Â Laemmli buffer. Samples were separated and analysed by 7.5 or 10% SDS-PAGE and then transferred onto Immobilon membranes. The membranes were blocked with 5% BSA and probed with antiactin for 1 h at room temperature. Immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibody and ECL reagents.
Statistical analysis
Results are calculated as the mean7s.e.m. Differences were assessed using the Student's t-test. P-value of o0.05 was considered significant.
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